The prevalence of the familial defective apolipoprotein B-100 (FDB) Arg 3500 Gln mutation in 525 unrelated hypercholesterolaemic Polish subjects was evaluated. DNA samples were screened for FDB mutation using SSCP method. Presence of mutation was confirmed using a mismatch MspI PCR strategy. Plasma lipid levels and clinical characteristics of 13 patients identified as carriers of the mutation and of their 23 affected relatives were analysed and compared with non-affected ones. In the affected individuals a variable expression of lipid concentrations and of atherosclerosis symptoms were observed. The prevalence of FDB Arg 3500 Gln mutation in hypercholesterolaemic Polish subjects (3.7%) seems to be similar to the frequency reported in other Caucasian hypercholesterolaemic populations. The estimated prevalence of the mutation in general Polish population is relatively high being 1/250. The same haplotype at the apoB locus in the carriers of this mutation in Poland as in other populations from Western Europe suggests its common origin. In one hypercholesterolaemic subject a non-hitherto described mutation was identified. It consisted in C?T transition in apoB codon 3492 leading to threonine to isoleucine substitution in 3492 position of apoB gene (Thr 3492 Ile). European Journal of Human Genetics (2001) 9, 836 ± 842.
Introduction
Familial defective apolipoprotein B-100 (FDB) is an autosomal dominantly inherited genetic disease first described by Innerarity et al 1 and characterised by hypercholesterolaemia and premature atherosclerosis.
Apo B-100 is the only protein of low density lipoproteins (LDL) and its binding to the LDL receptor is essential for the normal removal of LDL from plasma. The disorder is characterised by clinical and lipoprotein abnormalities very similar to familial hypercholesterolaemia caused by the LDL receptor deficiency. 2, 3 Recently numerous authors report that the symptoms in FDB are less severe than in disease caused by LDL receptor mutations. strongly reduces protein binding by the receptor. The occurrence of other kinds of mutations was also reported ± most of them very rare. They are either localised in the same 3500 site ± (Arg 3500 Trp) 9 ± or in its close proximity (Arg 3531 Cys). 10 FDB has been identified basing on DNA analysis in Caucasian populations of North America and in numerous European countries with a frequency ranging from 1:210 to 1:1250. It was however not found in Finland, Spain, Russia and Japan. 11 ± 14 The vast majority of the individuals carrying the apo B Arg 3500 Gln mutation has an identical apo B haplotype which strongly suggests that the mutation occurred on a single ancestral gene. 11, 15 Only a few independent mutations ie, accompanied by other haplotypes were described. 14 Five families carrying the apo B Arg3500Gln mutation were recently described in Poland. 16 In the present study the frequency of the FDB Arg 3500 Gln mutation in 525 unrelated hypercholesterolemic Polish subjects was evaluated.
Subjects
Five hundred and twenty-five unrelated patients (309 men and 216 women) with moderate and severe hypercholesterolaemia (LDL cholesterol 5160 mg/dl), aged 20 ± 82 years (mean age 57.5+9.7 years) recruited from the outpatient lipid clinic of the National Institute of Cardiology in Warsaw, Poland, were screened by single-strand conformation polymorphism (SSCP) analysis for the presence of FDB mutation. 351 (206 men and 145 women) had primary type IIA hyperlipoproteinaemia (HLP IIA) (triglycerides 5200 mg/ dl) and 174 of them (103 men and 71 women) had type IIB hyperlipoproteinaemia (HLP IIB) (triglycerides 5200 mg/dl but 5400 mg/dl). Sixty-five patients (42 men and 23 women) from HLP IIA group could be diagnosed as familial hypercholesterolaemia (FH clin ) basing on the clinical criteria according to Study Group European Atherosclerosis Society 17 ie, LDL cholesterol level above 190 mg/dl and the presence of tendon xanthomas in the patient or in a first-degree relative.
Seventy available relatives and 12 spouses of identified probands were subsequently investigated.
The study was approved by the Ethics Committee of National Institute of Cardiology. All the participants gave their informed consent for the investigation.
Methods
Blood samples were obtained after an overnight fast. Lipid levels were determined either before starting hypolipaemic therapy or after the period of at least 6 weeks without treatment. Total serum cholesterol (TC) and triglycerides (TG) were determined by enzymatic assays (Boehringer Mannheim). High density lipoprotein cholesterol (HDL-C) was determined after precipitation of apo B-100 containing After an initial denaturation step at 958C for 5 min, reaction was carried out for 35 cycles of amplification as follows: denaturation at 958C for 1 min, annealing at 608C for 1 min, and extension at 728C for 2 min. A final extension at 728C for 7 min was also performed. Twenty-five ml of reaction mixture was digested by the restriction endonuclease MspI (Amersham Life Science), using the conditions recommended by manufacturer. Digestion products were separated by electrophoresis at room temperature on 2% agarose gels, stained with ethidium bromide and viewed over ultra violet light. Sequencing was performed in DNA samples from the individual with atypical mutation (P132) and from a normal control. Exon 26 was amplified by polymerase chain reaction using oligonucleotide primers UOL and LOL and reaction conditions as described before. The products were purified using a Qiagen polymerase chain reaction kit and sequenced manually using the Thermo Sequenase Cycle Sequencing Kit (Amersham Life Science) under conditions recommended by the manufacturer.
Three biallelic markers were analysed to establish haplotypes at the apo B locus. 23 
Statistical analysis
Prevalence estimates of the mutation were expressed as percentages with 95% confidence intervals. Data for quantitative variables were expressed as mean values+SD. Lp(a) concentrations were expressed also as median values. Differences in means between FDB and non-FDB subjects were tested by the Mann-Whitney two-sample test. The lipid results were also adjusted by sex, age and family-connection using analysis of covariance. Statistical significance of the differences in the frequencies of the apo E alleles and of other qualitative variables was evaluated using w 2 or Fisher exact test. P-values lower than 0.05 were considered as statistically significant.
Results
SSCP screening of the whole group of 525 hypercholesterolaemic patients resulted in an initial identification of FDB mutation in 14 individuals. All the patients belonged to the HLP IIA group. The mutation was not found in any of 174 patients with HLP IIB. In one patient (P132) the SSCP pattern differed slightly from the patterns characteristic for both positive and negative results (Figure 1 ). In all but this one person with the atypical SSCP pattern the presence of the Arg 3500 Gln mutation has been confirmed by the mismatch MspI PCR method. All of them were heterozygous for the mutation. The calculated prevalence of the Arg 3500 Gln mutation was 2.5% in the whole hypercholesterolaemic group and 3.7% in the IIA type HLP group. In 65 patients with the clinical characteristics of familial hypercholesterolaemia (FH clin ) the frequency can be evaluated as 10.8% (Table 1) .
In the patient P132 with atypical SSCP pattern and non confirmed Arg 3500 Gln mutation further investigations by DNA sequencing revealed another kind of mutation in the same region of the apo B gene. A C?T transition in codon 3492 (ACT?ATT) which is producing a change from threonine to isoleucine in the encoded amino acid sequence was found (Thr 3492 Ile) (Figure 2 ). Such mutation was not described before. The patient was heterozygous for the mutation. Table 2 presents the clinical and biochemical characteristics of 14 probands with both mutations. Out of 13 subjects with the Arg 3500 Gln FDB mutation, eight had coronary artery disease (CAD) and two peripheral artery disease (PAD) symptoms and in four of them tendon xanthomas were found. The patient with Thr 3492 Ile mutation was highly hypercholesterolaemic, had first symptoms of angiographically confirmed CAD at the age of 39 years as well as angiographically confirmed PAD at the age of 38 years and had tendon xanthomatosis. All investigated relatives ie, his two sons and brother were carriers of the mutation, but their total and LDL cholesterol were not elevated. The brother of the proband had the first symptoms of angiographically confirmed CAD at the age of 50 years. Both sons (still young ± 20 and 22 years) were asymptomatic. The father of the proband died at the age of 73 years because of the third myocardial infarction (his first MI was at the age of 40 years).
Haplotype analysis of 10 families with FDB Arg 3500 Gln mutation demonstrated that the mutant allele segregated with the haplotype XbaI . The lack of DNA from family members of two probands (P82 and P537) and non-informative family pedigrees of another proband (P526) precluded unambiguous resolution of their haplotypes. Analysis of probands genotype ( Table 2 ) showed however that one of the two alleles could also represent the XbaI A comparison of the results of lipid and lipoprotein determinations and of clinical characteristics in 36 FDB subjects (13 probands and their affected relatives) with 44 non-FDB relatives is shown in Table 3 . The carriers of the Arg 3500 Gln mutation had markedly higher mean TC and LDL-C levels. The median Lp(a) level was similar in both groups, but in 
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M Bednarska-Makaruk et al 838 affected subjects Lp(a) level above 30 mg/dl occurred more frequently than in nonaffected ones (31.4% vs 16.3%, respectively). 22.6% of adult FDB subjects (above 20 years of age) had tendon xanthomas. Cardiovascular disease as defined by angina or history of MI was present in 38.7% of the adult FDB subjects as compared with 10.3% in their non-FDB relatives. Comparison of lipid and lipoprotein levels in affected and non-affected family members showed some degree of overlapping of the results. Four young FDB mutation carriers had LDL-C in normal or in the upper range of normal levels. Two diabetic FDB patients had also hypertriglyceridaemia. Some non-FDB relatives and spouses showed lipid abnormalities: mostly mild or moderate hypercholesterolaemia, and some of them mild hypertriglyceridaemia.
Lipid and lipoprotein levels did not differ significantly between FDB patients carriers of various apolipoprotein E allele (data not shown).
Discussion
In this study Polish unrelated individuals with moderate and severe hypercholesterolaemia were screened for the presence of the FDB Arg 3500 Gln mutation. The mutation was detected 26 an estimate of the frequency of the Arg 3500 Gln mutation in Polish population was 10.8%60.2% plus 2.1%6(19% ± 0.2%)&1/250. In our study relatively high frequency (10.8%) of the mutation was found among clinically diagnosed FH patients. In most other studies based on the same clinical criteria FDB frequency in this group was reported to be 2 ± 3%.
14,24 A higher frequency (12%) was stated only in Switzerland. 5 Recently in Poland FDB mutation was found in five of 30 families (17%) with clinical signs of familial hypercholesterolaemia. 16 It suggests that FDB mutation may be a rather frequent cause of clinically recognised familial hypercholesterolaemia in Poland.
Comparison of the lipid parameters in FDB subjects and their non-FDB relatives (in which environmental and other genetic factors were similar) revealed that cholesterol concentration was not fully informative for FDB diagnosis as TC and LDL-C concentrations in subjects with and without mutation were overlapping to some extent. Such observations were also noted in other studies. 4, 6, 27 DNA analysis in the relatives of FDB mutation carriers should therefore be strongly recommended as a method of an early identification of other carriers. In one of the examined hypercholesterolaemic patients a new mutation was detected. It was localised in codon 3492 of the apo B gene causing threonine to isoleucine substitution. The patient-carrier of this mutation was hypercholesterolaemic and had symptoms of premature atherosclerosis in coronary and peripheral arteries, tendon xanthomatosis and family history of premature atherosclerosis. All investigated relatives of the proband were carriers of the mutation and all were normocholesterolaemic. However as it was observed for the Arg 3500 Gln mutation, the TC and LDL-C concentrations might be not fully informative for FDB diagnosis. The Thr 3492 Ile mutation is situated in close proximity of the typical Arg 3500 Gln one. To determine the influence of this mutation on the apo B-100 ligand function, the study of binding affinity of proband's LDL to LDL receptor is necessary.
A high prevalence of another kind of apo B mutation ± the Arg 3531 Cys mutation was recently stated in Denmark 7 and in
France. 28 The frequency of this kind of mutation in Poland
has not yet been established. In summary, our study showed that the prevalence of the Arg 3500 Gln mutation in Polish hypercholesterolaemic patients was 3.7% which was similar to the frequency detected in hypercholesterolaemic groups in several other European countries. The estimated prevalence of the mutation in the general Polish population could be relatively high ± 1/250. The same haplotype at the apo B locus in the carriers of this mutation in Poland suggests its common origin with other populations from Western Europe. A not hitherto reported kind of mutation in apo B gene ± a Thr 3492 Ile mutation was found in one hypercholesterolaemic subject with early CAD symptoms. The determination of the influence of the mutation on LDL binding to LDL receptor is necessary.
